Acacia
drugOn this page
Also known as Acacia arabicaAcacia circummarginata resinAcacia cufodontii resinAcacia mucilageAcacia oxyosprion resinAcacia powderAcacia rupestris resinAcacia senegalAcacia senegal gumAcacia senegal resinAcacia seyalAcacia spinosa resinAcacia verek resinAcacia volkii resinspray-driedFEMA NO. 2001Gum acaciaGum arabic (acacia senegal)Gum arabic (acacia seyal)
Summary
Acacia (CHEMBL2108172) is a phase-3 clinical-stage unknown; indicated across 3 conditions including rheumatoid arthritis and metabolic syndrome x.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 3 conditions
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108172 |
| Name | Acacia |
| Type | Unknown |
| Max phase | 3 |
Also known as: Acacia, Acacia arabica, Acacia circummarginata resin, Acacia cufodontii resin, Acacia mucilage, Acacia oxyosprion resin, Acacia powder, Acacia rupestris resin, Acacia senegal, Acacia senegal gum, Acacia senegal resin, Acacia seyal
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| rheumatoid arthritis | 2 | MONDO:0008383 | EFO:0000685 |
| metabolic syndrome X | 2 | MONDO:0011565 | EFO:0000195 |
| sickle cell disease | 1 | MONDO:0011382 | MONDO:0011382 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 2 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02154594 | PHASE4 | COMPLETED | The Efficacy of Acacia Catechu Mouthrinse as Antiplaque and Antigingivitis Agent in Fixed Orthodontic Appliance Patients. |
| NCT04381871 | PHASE2/PHASE3 | UNKNOWN | Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients |
| NCT05599399 | Not specified | COMPLETED | Impact of Gum Acacia on Chronic Kidney Disease Patients |
| NCT06805292 | Not specified | COMPLETED | Evaluation of Acacia Catechu and Low-Level Laser in the Treatmentof Stage II Periodontitis |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.